Clinical Trials Browser

Phase 1/2 × Adenocarcinoma × sintilimab × Clear all

NCT04202601 2019-12-19

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Phase 1/2 Unknown

Adenocarcinoma